EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Folic Acid‐Modified Ginger‐Derived Exosome‐Like Nanoparticles Co‐Delivering Sunitinib Suppress Renal Cell Carcinoma via PI3K‐Akt Pathway Inhibition, P‐gp Downregulation, and Macrophage Reprogramming

Haoyu Xu iD, Daixing Hu, Shixue Liu, Lei Yang, Junwu Li, Yuanyuan Bai, Guozhi Zhao, Wei Tang, Li Jiang iD

Advanced Science · 2026-01 · 13 (6)

DOI: 10.1002/advs.202512563 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 17.11.2025. Verfasst von Haoyu Xu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China. Hauptthemen laut MEDLINE: Zingiber officinale, Sunitinib, Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chongqing Municipal Key Research and Development Program of China, Natural Science Foundation of Chongqing Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Renal cell carcinoma (RCC) is a malignant tumor with highly recurrent and metastatic capability. The current therapies for RCC are limited by drug resistance and toxic side effects. This study introduces an innovative approach that combines ginger‐derived exosome‐like nanoparticles (GELNs) with sunitinib (Su) and folic acid‐polyethylene glycol (FA‐PEG, FPD) in an active‐passive targeting strategy to explore its multi‐mechanism and synergistic therapeutic effects on RCC. GELNs are extracted via differential centrifugation combined with sucrose gradient ultracentrifugation. Metabolomics and network pharmacology predicted that GELNs may exert their anticancer efficacy via the PI3K‐Akt signaling pathway, which is subsequently validated through in vitro experiments. By loading Su and modifying it with FPD, FPD‐GELNs/Su is constructed. The FPD modification significantly enhanced tumor targeting and amplified the Su sensitivity by reducing ABCB1/P‐gp expression induced by GELNs. In vivo experiments revealed that FPD‐GELNs/Su promoted M1 macrophage polarization and increased immune T‐cell infiltration by remodeling the tumor microenvironment, leading to significant inhibition of tumor growth and lung metastasis without causing notable liver or kidney toxicity. This study integrates network pharmacology with targeted delivery strategies, elucidating the mechanisms by which FPD‐GELNs/Su inhibits RCC progression through multiple pathways, providing new insights for the development of precise and low‐toxicity nano‐therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Zingiber officinaleSunitinibCarcinoma, Renal CellKidney NeoplasmsNanoparticle Drug Delivery SystemLung NeoplasmsNanoparticlesFolic AcidPolyethylene GlycolsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktSignal TransductionMacrophagesTumor MicroenvironmentLymphocytes, Tumor-InfiltratingT-Lymphocyte SubsetsNetwork PharmacologyInjections, IntravenousHumansFemaleAnimalsMiceMice, Inbred BALB CXenograft Model Antitumor AssaysAntineoplastic AgentsTyrosine Kinase Inhibitors

Stichwörter der Autor:innen

ABCB1/P‐gpPI3K‐Akt signaling pathwayginger‐derived exosome‐like nanoparticlesrenal cell carcinomasunitinibtumor‐associated macrophages

Substanzen

Folic AcidSunitinibPolyethylene GlycolsNanoparticle Drug Delivery SystemPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktAntineoplastic AgentsTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
  • Department of Urology, The Affiliated Yongchuan Hospital of Chongqing Medical University, Chongqing, 402160, China.
  • Department of Breast and Thyroid Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China.
  • Department of Urology, The Shapingba Hospital, Chongqing University (People's Hospital of Shapingba District), Chongqing, 400030, China.

ORCID-Profile: Haoyu Xu, Li Jiang

Förderung

  • Chongqing Municipal Key Research and Development Program of China
  • Natural Science Foundation of Chongqing Municipality

Zitieren

APA

Xu, H., Hu, D., Liu, S., Yang, L., Li, J., Bai, Y., Zhao, G., Tang, W., & Jiang, L. (2026). Folic Acid‐Modified Ginger‐Derived Exosome‐Like Nanoparticles Co‐Delivering Sunitinib Suppress Renal Cell Carcinoma via PI3K‐Akt Pathway Inhibition, P‐gp Downregulation, and Macrophage Reprogramming. Advanced Science, 13(6). https://doi.org/10.1002/advs.202512563

Vancouver

Xu H, Hu D, Liu S, Yang L, Li J, Bai Y, et al. Folic Acid‐Modified Ginger‐Derived Exosome‐Like Nanoparticles Co‐Delivering Sunitinib Suppress Renal Cell Carcinoma via PI3K‐Akt Pathway Inhibition, P‐gp Downregulation, and Macrophage Reprogramming. Advanced Science. 2026;13(6). doi:10.1002/advs.202512563

BibTeX
@article{Xu2026,
  author = {Xu, Haoyu and Hu, Daixing and Liu, Shixue and Yang, Lei and Li, Junwu and Bai, Yuanyuan and Zhao, Guozhi and Tang, Wei and Jiang, Li},
  title = {Folic Acid‐Modified Ginger‐Derived Exosome‐Like Nanoparticles Co‐Delivering Sunitinib Suppress Renal Cell Carcinoma via PI3K‐Akt Pathway Inhibition, P‐gp Downregulation, and Macrophage Reprogramming},
  journal = {Advanced Science},
  year = {2026},
  volume = {13},
  number = {6},
  doi = {10.1002/advs.202512563}
}
Kostenlos starten →